|Title:||Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression.|
Ono, Masahiro https://orcid.org/0000-0002-2497-039X (unconfirmed)
Nakamoto, Yuji https://orcid.org/0000-0001-5783-8048 (unconfirmed)
|Author's alias:||上田, 真史|
|Journal title:||Molecular imaging and biology|
|Abstract:||【Purpose】We aimed to develop a gallium-68 (Ga-68)-labeled single-chain variable fragment (scFv) targeting the human epidermal growth factor receptor 2 (HER2) to rapidly and noninvasively evaluate the status of HER2 expression. 【Procedures】Anti-HER2 scFv was labeled with Ga-68 by using deferoxamine (Df) as a bifunctional chelate. Biodistribution of [(68)Ga]Df-anti-HER2 scFv was examined with tumor-bearing mice and positron emission tomography (PET) imaging was performed. The changes in HER2 expression after anti-HER2 therapy were monitored by PET imaging. 【Results】[(68)Ga]Df-anti-HER2 scFv was obtained with high radiochemical yield after only a 5-min reaction at room temperature. The probe showed high accumulation in HER2-positive xenografts and the intratumoral distribution of radioactivity coincided with HER2-positive regions. Furthermore, [(68)Ga]Df-anti-HER2 scFv helped visualize HER2-positive xenografts and monitor the changes in HER2 expression after anti-HER2 therapy.【Conclusion】[(68)Ga]Df-anti-HER2 scFv could be a promising probe to evaluate HER2 status by in vivoPET imaging, unless trastuzumab is prescribed as part of the therapy.|
|Description:||First online: 22 July 2014|
|Rights:||The final publication is available at Springer via http://dx.doi.org/10.1007/s11307-014-0769-5.|
The full-text file will be made open to the public on 22 July 2015 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.
This is not the published version. Please cite only the published version.
|Appears in Collections:||Journal Articles|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.